@article {AGOLLI6239, author = {LINDA AGOLLI and MAURIZIO VALERIANI and LUCA NICOSIA and STEFANO BRACCI and VITALIANA DE SANCTIS and GIUSEPPE MINNITI and RICCARDO MAURIZI ENRICI and MATTIA FALCHETTO OSTI}, title = {Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach}, volume = {35}, number = {11}, pages = {6239--6245}, year = {2015}, publisher = {International Institute of Anticancer Research}, abstract = {Aim: Stage IV non-small cell lung cancer (NSCLC) is characterized by poor prognosis. Palliative chemotherapy and/or best supportive care are considered standard treatment. Nevertheless, for patients with limited distant metastases (1-5 metastases), called oligometastatic disease, better prognosis has been observed. We evaluated response rate, survival, time to progression and toxicity in oligometastatic/oligorecurrent NSCLC patients treated with stereotactic body radiotherapy (SBRT) delivered to all active sites in the lung. Patients and Methods: Twenty-nine lung metastases in 22 patients affected by oligometastatic/oligorecurrent NSCLC were treated with SBRT to all active sites of disease. Inclusion criteria were: controlled primary tumor with complete response or stable disease after surgery/radiotherapy/combined therapy; <=4 synchronous or metachronous lung metastases at the time of treatment; no other active sites of distant metastases. Results: Response to treatment was as follows: complete response in 21\% of lesions, partial response in 69\% of metastases, stable disease in 10\%. Ninenty-one percent of patients had complete metabolic response, and 9\% had a partial metabolic response. Median follow-up was 18 months. The 1-year and 2-year OS was 86\% and 49\%, respectively. The 1-year and 2-year PFS was 79\% and 40\%, respectively. Median time to progression and median OS were 18 months and 24 months, respectively. Local control was 93\% at 1 year and 64\% at 2 years. Overall, acute toxicity occurred in 18\% (4/22) of patients; two patients experienced grade 2 pneumonitis. Grade <=2 late toxicity occurred in 50\% of patients. No grade >=3 toxicities were recorded. Conclusion: Aggressive stereotactic radiotherapy is a feasible and well-tolerated treatment for oligometastatic/oligorrecurrent NSCLC patients with lung metastases offering longer survival. Ablative radio therapy has a potential role in the management of well-selected stage IV NSCLC patients while increasing their quality of life and survival.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/35/11/6239}, eprint = {https://ar.iiarjournals.org/content/35/11/6239.full.pdf}, journal = {Anticancer Research} }